About CUREO
CUREO is a company based in Dusseldorf (Germany) founded in 2018 by Thomas Saur and Stefan Arand. CUREO has raised $4.06 million across 1 funding round from investors including Nomainvest and TechVision Fonds. CUREO offers products and services including CUREO. CUREO operates in a competitive market with competitors including Virtuleap, NeuroFlex®, VisionweaRx, Planifest and Oqupi, among others.
- Headquarter Dusseldorf, Germany
- Founders Thomas Saur, Stefan Arand
-
Sectors
Technology
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Cureosity Gmbh
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$4.06 M (USD)
in 1 rounds
-
Latest Funding Round
$4.06 M (USD), Series A
Jun 24, 2024
-
Investors
Nomainvest
& 1 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of CUREO
CUREO offers a comprehensive portfolio of products and services, including CUREO.
Virtual reality solution for gamified rehabilitation therapy
Funding Insights of CUREO
CUREO has successfully raised a total of $4.06M through 1 strategic funding round. The most recent funding activity was a Series A round of $4.06 million completed in June 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in CUREO
CUREO has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Nomainvest and TechVision Fonds.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
TechVision Fonds is engaged in early-stage venture capital investments.
|
Locked | Locked | Locked | |
|
Noel family investments are managed by this family office.
|
Locked | Locked | Locked |
Investor details for CUREO
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by CUREO
Investment portfolio details for CUREO
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - CUREO
Detailed financials for CUREO
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cureo Comparisons
Peer comparison for CUREO
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of CUREO
CUREO operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Virtuleap, NeuroFlex®, VisionweaRx, Planifest and Oqupi, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Cognitive skills are assessed and trained through a VR platform.
|
|
| Locked | Locked | Locked |
Brain function is evaluated through virtual reality protocols.
|
|
| Locked | Locked | Locked |
Offers VR tests for diagnosing dyslexia, dyscalculia, and dysgraphia efficiently.
|
|
| Locked | Locked | Locked |
Provides a VR platform for effective habitual training programs.
|
|
| Locked | Locked | Locked |
Develops VR-based systems for rehabilitation therapy and patient recovery.
|
Detailed competitors of CUREO
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cureo
Complete news archive for CUREO
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CUREO
CUREO was founded in 2018 and raised its 1st funding round 6 years after it was founded.
CUREO is headquartered in Dusseldorf, Germany. It is registered at Dusseldorf, North Rhine-westphalia, Germany.
Caesar Van Heyningen is the current CEO of CUREO.
CUREO is a funded company, having raised a total of $4.06M across 1 funding round to date.
CUREO was established in 2018 in Dusseldorf, Germany, within the healthcare technology sector. Virtual reality devices are created by the company for use in rehabilitation settings. These systems address various conditions related to motorsensory and cognitive impairments. Therapeutic applications are integrated through immersive VR experiences to support patient recovery processes in institutional environments.
CUREO's top competitors include Virtuleap, NeuroFlex® and VisionweaRx.
CUREO offers CUREO.
CUREO has 2 investors. Key investors include Nomainvest, and TechVision Fonds.